Bold Capital Partners
VC Fund
Santa Monica, United States
Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.
- Total investments:
- 130
- Last investment:
- Lead investor:
- 22%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Bold Capital Partners invests in
Stages Bold Capital Partners invests in
Countries Bold Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$15M
- Series A
- $6M–$37M
- Series B
- $15M–$58M
Investment Focus
Industry
- Health Care 21 (16%)
- Software 17 (13%)
- Biotechnology 17 (13%)
- Artificial Intelligence 12 (9%)
- Medical 9 (7%)
Stage
- Series A 42 (32%)
- Series B 25 (19%)
- Seed 24 (18%)
- Funding Round 7 (5%)
- Venture - Series Unknown 5 (4%)
Country
- United States 63 (48%)
- Hong Kong 2 (2%)
- India 1 (1%)
- Canada 1 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Teymour Boutros-Ghali
Managing Partner
|
Managing Partner | Total investments: 12 | Find email | |
Will Borthwick
Principal
|
Principal | Total investments: 1 | Find email | |
Emilio Diez Barroso
Partner
|
Partner | Total investments: 0 | Find email | |
Felicia Hsu
Investor
|
Investor | Total investments: 0 | Find email | |
Maxx Bricklin
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
KeyCare
|
KeyCare is a virtual care platform powered by Epic that was created to assist forward-thinking health systems in increasing patient access and quality by enhancing the alternatives available for virtual care. | $27.4M / Series A / Mar 03, 2026 | |
Evergreen
|
Omeat is a game-changing solution to the environmental, health, and animal welfare challenges posed by animal agriculture. They offer real meat grown from cells outside the animal that's every bit as delicious and nourishing as business-as-usual meat, but no sacrifice is required. | $6M / Series A / Feb 04, 2026 | |
MagicCube
|
MagicCube is the Software Defined Trust (SDT) category with its software TEE-based platform. The technology enables large-scale deployment and management of IoT and mobile- secure solutions to consumers. | $10M / Venture - Series Unknown / Jan 11, 2026 | |
Prorata.AI
|
ProrataAI builds technology that enables generative AIs to properly attribute contributing content and share revenues on a per-use basis. | $40M / Series B / Sep 05, 2025 | |
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $44M / Series C / Aug 12, 2025 | |
Aqtual
|
Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology and biochemistry for chronic disease. | $31M / Series B / Jul 10, 2025 | |
Centivax
|
Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $45M / Series A / Jul 08, 2025 | |
Syntis Bio
|
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M / Series A / Jul 01, 2025 | |
Near Space Labs
|
Near Space Labs is an aerial imagery and earth observation company, Near Space Labs' imagery makes it easy to monitor assets and gain remote access over broad or specific areas. Near Space Labs offers cloud-based delivery of fully processed images through its API. The company provides frictionless, affordable imaging for insurance, utilities,infrastructure, conservation, smart cities, retail, energy, government, and disaster response. | $20M / Series B / Apr 29, 2025 | |
Chef Robotics
|
Chef Robotics is a robotics and artificial intelligence company serving the food industry. The company was founded in 2019 and is headquartered in San Francisco, California. | $20.6M / Series A / Mar 31, 2025 | |
| See all 130 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bold Capital Partners invest in?
Bold Capital Partners invests primarily in Health Care, Software and Biotechnology startups, most often at Series A and Series B stage. Most of the 130 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bold Capital Partners's check size?
Bold Capital Partners typically joins rounds of $2M–$15M at Seed, $6M–$37M at Series A and $15M–$58M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bold Capital Partners participates in.
How do I contact Bold Capital Partners?
Public channels for Bold Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bold Capital Partners?
The team at Bold Capital Partners includes Teymour Boutros-Ghali (Managing Partner), Will Borthwick (Principal) and Emilio Diez Barroso (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
